The California Institute for Regenerative Medicine (CIRM) has been in business for a decade now, and has not come close to fulfilling the promises made during the 2004 election campaign. As yet, the “cures for California” have not materialized.
Arguably, developing clinical applications in ten years was always over-optimistic, to be polite (the term “hype” seems appropriate). A new President and CEO, C. Randal Mills, took charge last year and is responding to the situation by launching what he calls CIRM 2.0, in an effort to “accelerate the development of stem cell treatments for patients with unmet medical needs.” (His video presentation is here.)
About two-thirds of the 3 billion dollars of public funds that voters allocated has been spent, and there are rumblings about returning to the ballot process for more money. We may expect those speculations to become more prominent, though Mills insists that his reforms are not tied to electoral expectations.
This is only the latest attempt at structural reform. The Little Hoover Commission examined CIRM’s workings in 2008–9. The Institute of Medicine produced a report in 2012, as well a controversial assessment about egg procurement in 2007. There have also been several state audits, as well as newspaper criticism and rumblings in Sacramento. CGS testified before both investigations (Hoover; IoM), as well as directly to the CIRM Board and Standards and Practices Working Group [pdf], and produced a critical Progress Report [pdf] nine years ago.
Perhaps the new effort will work to improve the efficiency of the operation.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.